ArticleNPJ Parkinson's disease2023
Elucidating causative gene variants in hereditary Parkinson's disease in the Global Parkinson's Genetics Program (GP2).
Article in NPJ Parkinson's disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 31 citations in OpenAlex.
- Parkinson's disease genetics across diverse ancestries: an observational genetic study of causal and risk variants with translational implications.The Lancet. Neurology · 2026Observational
- Article
- Genetic Testing by Age at Onset in Parkinson Disease.JAMA neurology · 2026Article
- Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Repeat expansions in Parkinson's disease and parkinsonism across ancestries: insights from a global genetic cohort.medRxiv : the preprint server for health sciences · 2026Article
- Article
- Multi-ancestry analysis ofmedRxiv : the preprint server for health sciences · 2026Article
- The Global Parkinson's Genetics Program (GP2): Advancing genetic discovery and capacity building worldwide.Journal of Parkinson's disease · 2026Review
- Association of LRRK2 p.A419V with Parkinson's Disease in East Asians and analysis of age at onset.NPJ Parkinson's disease · 2026Article
- Two lysosomal genes ATP13A2 and GBA1 interact to drive neurodegeneration.Molecular neurodegeneration · 2026Article
- Progression ofFrontiers in aging neuroscience · 2026Article
- Rare but Relevant? Assessing Variants in Dystonia-Linked Genes in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- How many do we miss? - Evaluation of age at onset and family history as selection criteria for genetic testing in Parkinson's disease.medRxiv : the preprint server for health sciences · 2025Article
- ThemedRxiv : the preprint server for health sciences · 2025Article
- The Global Landscape of Genetic Variation in Parkinson's disease: Multi-Ancestry Insights into Established Disease Genes and their Translational Relevance.medRxiv : the preprint server for health sciences · 2025Article
- The LRRK2 p.L1795F variant causes Parkinson's disease in the European population.NPJ Parkinson's disease · 2025Article
- Clinical and functional evidence for the pathogenicity of the LRRK2 p.Arg1067Gln variant.NPJ Parkinson's disease · 2025Article
- Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson´s disease.NPJ Parkinson's disease · 2025Article
- New insights from a Malaysian real-world deep brain stimulation cohort.Journal of Parkinson's disease · 2025Article
- A Global Perspective ofGenes · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
24 authors at 9 institutions in 5 countries.
Funding
Abstract
The Monogenic Network of the Global Parkinson's Genetics Program (GP2) aims to create an efficient infrastructure to accelerate the identification of novel genetic causes of Parkinson's disease (PD) and to improve our understanding of already identified genetic causes, such as reduced penetrance and variable clinical expressivity of known disease-causing variants. We aim to perform short- and long-read whole-genome sequencing for up to 10,000 patients with parkinsonism. Important features of this project are global involvement and focusing on historically underrepresented populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.